


Factor XIa Control

REF	Catalogue number	1188
LOT	Batch code	HHK2317
	Use by	2018-09
	Upper limit of temperature	-20°C

Activity after reconstitution in 4.0 mL water:

2.8 mU/mL Acceptance range:
2.4 – 3.2 mU/mL

1. INTENDED USE

For In Vitro Laboratory Use Only – Not for Diagnostic Use

The FXIa Control is intended for direct use with the Rox Factor XIa Kit, Ref 110050 (Rossix AB). No dilution should be made prior to assay.

2. PROPERTIES

Lyophilized preparation of human Factor XIa calibrated against the NIBSC reference reagent for Activated Blood Coagulation Factor XI (FXIa), Human, 11/236 using the Rox Factor XIa kit Ref 110050.

Activity after reconstitution in 4.0 mL water:

2.8 mU/mL

Acceptance range: 2.4 – 3.2 mU/mL

The above Factor XIa activity applies only to Lot#HHK2317.

No dilution of the control should be made prior to assay when using the Rox Factor XIa kit. The control is designed for direct use in the assay.

3. HANDLING

Allow ampoule to warm to room temperature before reconstitution. Reconstitute with 4 ml of purified water and leave to stand at room temperature for 5 min with intermittent gentle mixing prior to use.

4. PACKAGE

One package contains 10 vials.

5. STABILITY

A reconstituted vial is stable for 8 hours at 2-8°C. An unopened vial is stable until the expiry date printed on the label.

6. STORAGE


Unopened vials should be stored in the dark at or below -20°C.

7. CAUTION

This preparation is not for administration to humans.

The product contains material of human blood/plasma origin. Although the starting material was tested prior to initiation of the manufacturing process, and was found negative or nonreactive for anti-HIV-1/2, HIV-1 antigen(s), HBsAg, STS, anti-HCV, anti-HBcore and anti-HTLV I & II caution should be used when handling this material. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory's safety procedures. Such safety procedures should include the wearing of protective gloves.

8. CONTACT INFORMATION

	Rossix AB	Phone: +46 31 706 8965
	Taljegardsgatan	Fax: +46 31 706 8966
	SE-431 53	info@rossix.com
	Sweden	www.rossix.com

Last revision date: September 20, 2013